Consequences of the Use of Anabolic-Androgenic Steroids on Female Athletes’ Fertility

  • Juan Manuel García-MansoEmail author
  • Teresa Valverde Esteve


Evidence suggests that many athletes use anabolic-androgenic steroids (AAS), especially those who practice strength modalities. In recent years, regrettably, the use of AAS has spread among many women athletes. Besides being a prohibited practice, the use of AAS can influence negatively the health of these athletes. Among these numerous negative effects, evidence supports the abuse of steroids can adversely affect the fertility and reproductive organs of women severely.


Female fertility Anabolic-androgenic steroids Exercise Female reproductive system 


  1. 1.
    Büttner A, Thieme D. Side effects of anabolic androgenic steroids: pathological findings and structure–activity relationships. In: Thieme D, Hemmersbach P, editors. Doping in sports: biochemical principles, effects and analysis. Berlin: Springer; 2010. p. 459–84.Google Scholar
  2. 2.
    Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Christakopoulos A, Ericsson M, Garle M, Villén T, Beck O. Anabolic androgenic steroids are more common in society than in sports. Lakartidningen. 2013;110(39–40):1732–4.PubMedGoogle Scholar
  5. 5.
    Abrahin OSC, de Sousa EC, Santos AM. Prevalence of the use of anabolic-androgenic steroids in Brazil: a systematic review. Subst Use misuse. 2014;49(9):1156–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Stubbe JH, Chorus AM, Frank LE, Hon O, Heijden PG. Prevalence of use of performance enhancing drugs by fitness centre members. Drug Test Anal. 2014;6(5):434–8.PubMedGoogle Scholar
  7. 7.
    Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. J Am Med Assoc. 1985;253(19):2871–3.CrossRefGoogle Scholar
  8. 8.
    Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA. 1993;270(10):1217–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Pereira HMG, Sardela VF. Stimulant doping agents used in Brazil: prevalence, detectability, analytical implications, and challenges. Subst Use Misuse. 2014;49(9):1098–114.CrossRefPubMedGoogle Scholar
  10. 10.
    Thorlindsson T, Halldorsson V. Sport, and use of anabolic androgenic steroids among Icelandic high school students: a critical test of three perspectives. Subst Abuse Treat Prev Policy. 2010;5:32.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dunn M, White V. The epidemiology of anabolic–androgenic steroid use among Australian secondary school students. J Sci Med Sport. 2011;14(1):10–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Johnston L, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975–2011. Volume I: secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan; 2012.Google Scholar
  13. 13.
    Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21(3):225–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Petersson A, Garle M, Granath F, Thiblin I. Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care: a controlled retrospective cohort study. Drug Alcohol Depend. 2006;81(3):215–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Santora LJ, Marin J, Vangrow J, Minegar C, Robinson M, Mora J, Frieds G. Coronary calcification in body builders using anabolic steroids. Prev Card. 2006;9(4):198–201.CrossRefGoogle Scholar
  16. 16.
    Paolo M D, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, Arbustini E. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol. 2007;114(1):114–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Sports Med. 1995;19(5):326–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxic Lett. 2005;158(3):167–75.CrossRefGoogle Scholar
  19. 19.
    Melnik B, Jansen T, Grabbe S. Abuse of anabolic‐androgenic steroids and bodybuilding acne: an underestimated health problem. J Deut Dermat Gesell. 2007;5(2):110–7.CrossRefGoogle Scholar
  20. 20.
    Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids. Ped Clin N Am. 2007;54(4):677–90.CrossRefGoogle Scholar
  21. 21.
    Wu FCW. Endocrine aspects of anabolic steroids. Clin Chem. 1997;43(7):1289–92.PubMedGoogle Scholar
  22. 22.
    Clark AS, Costine BA, Jones BL, Kelton-Rehkopf MC, Meerts SH, Nutbrown-Greene LL, Henderson LP. Sex-and age-specific effects of anabolic androgenic steroids on reproductive behaviors and on GABAergic transmission in neuroendocrine control regions. Brain Res. 2006;1126(1):122–38.CrossRefPubMedGoogle Scholar
  23. 23.
    Elliot DL, Goldberg L. Women and anabolic steroids. Anab Steroids Sport Exerc. 2000;2:225–46.Google Scholar
  24. 24.
    Burger HG. Androgen production in women. Fertil Steril. 2002;77(4):3–5.CrossRefGoogle Scholar
  25. 25.
    Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108–17.CrossRefPubMedGoogle Scholar
  26. 26.
    Burger HG. Androgen production in women. Fertil Steril. 2002;77(4):3–5.CrossRefGoogle Scholar
  27. 27.
    Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obs Gynecol. 1974;118(6):793–8.CrossRefGoogle Scholar
  28. 28.
    Obasanjo IO, Cline JM, Schmotzer S, Weaver DS. Nandrolone decanoate causes pathologic changes in the uterus of surgically postmenopausal female cynomolgus macaques. Menopause. 1998;5(3):163–8.PubMedGoogle Scholar
  29. 29.
    Sprando RL, Collins TF, Black TN, Olejnik N, Grundel E, Ruggles DI. Effects of androstenedione on in utero development in rats. Food Chem Toxicol. 2004;42(6):917–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Rubiera-Gerez JR, Frei F, Camargo IC. Histological assessment of ovaries and uterus of rats subjected to nandrolone decanoate treatment. Contraception. 2005;72:77–80.CrossRefGoogle Scholar
  31. 31.
    Cherici-Camargo IC, Barreiros-De Souza R, Mesquita S, Chuffa LG, Frei F. Ovarian histology and follicular score in female rats treated with nandrolone decanoate and submitted to physical effort. Acta Biol Hung. 2009;60(3):253–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Cherici-Camargo IC, Gaspar ALC, Frei F, Mesquita SD. Effects of androgenic anabolic steroids on the uterus and reproductive parameters of adult female rats. Rev Bras Ginecol Obs. 2009;31(9):453–60.CrossRefGoogle Scholar
  33. 33.
    De Almeida-Chuffa LG, de Souza RB, Frei F, Mesquita S, Cherici-Camargo IC. Nandrolone decanoate and physical effort: histological and morphometrical assessment in adult rat uterus. Anatom Record. 2011;294(2):335–41.CrossRefGoogle Scholar
  34. 34.
    Karbalay-Doust S, Noorafshan A, Ardekani FM, Mirkhani H. The reversibility of sperm quality after discontinuing nandrolonendecanoate in adult male rats. Asian J Androl. 2007;9:235–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Bordbar H, Mesbah F, Talaei T, Dehghani F, Mirkhani H. Modulatory effect of gonadotropins on rats’ ovaries after nandrolone decanoate administration: a stereological study. Iran J Med Sci. 2014;39(1):44–50.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Howe GR, Morello CJ. Effects of an anabolic steroid on reproduction in female rats. Steroid. 1985;45(6):495–501.CrossRefGoogle Scholar
  37. 37.
    Bronson FH, Nguyen KQ, Delarosa J. Effect of anabolic steroid on physiological characteristics of female mice. Physiol Behav. 1996;59:49–55.CrossRefPubMedGoogle Scholar
  38. 38.
    Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med. 1997;18(7):557–62.CrossRefPubMedGoogle Scholar
  39. 39.
    Blasberg ME, Langan CJ, Clark AS. The effects of alphathyltestosterone, methandrostenolone and nandrolone decanoate on the rat estrous cycle. Physiol Behav. 1997;61:265–72.CrossRefPubMedGoogle Scholar
  40. 40.
    Graham S, Kennedy M. Recent developments in the toxicology of anabolic steroids. Drug safety. 1990;5(6):458–76.CrossRefPubMedGoogle Scholar
  41. 41.
    Kao LW, Weisz J. Direct effect of testosterone and its 5alpha-reduced metabolites on pituitary LH and FSH release in vitro: change in pituitary responsiveness to hypothalamic extract. Endocrinology. 1975;96(2):253–60.CrossRefPubMedGoogle Scholar
  42. 42.
    Strauss JF, Martinez F, Kiriakidou M. Placental steroid hormone synthesis: unique features and unanswered questions. Biol Reprod. 1996;54(2):303–11.CrossRefPubMedGoogle Scholar
  43. 43.
    Penatti CA, Oberlander JG, Davis MC, Porter DM, Henderson LP. Chronic exposure to anabolic androgenic steroids alters activity and synaptic function in neuroendocrine control regions of the female mouse. Neuropharmacology. 2011;61(4):653–64.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Friedl KE, Yesalis CE. Self-Treatment of Gynecomastia in Bodybuilders Who Use Anabolic Steroids. Case Reports. Phys Sportsmed. 1989;17(3):67–71.CrossRefPubMedGoogle Scholar
  45. 45.
    Ruiz-Cortés ZT. Gonadal sex steroids: production, action and interactions in mammals. In: Ostojic SM, editor. Steroids—from physiology to clinical medicine. Rijeka: Intech; 2012. doi:10.5772/46119.Google Scholar
  46. 46.
    Anderson E. In vivo and in vitro effects of androgens on rat ovarian granulosa cells. Am J Obstet Gynecol. 1989;160(4):782–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Anderson E, Little B, Lee GS. Androgen-induced changes in rat ovarian granulosa cells in vitro. Tiss Cell. 1987;19(2):217–34.CrossRefGoogle Scholar
  48. 48.
    Mobini-Far HR, Ågren G, Lindqvist AS, Marmendal M, Fahlke C, Thiblin I. Administration of the anabolic androgenic steroid nandrolone decanoate to female rats causes alterations in the morphology of their uterus and a reduction in reproductive capacity. Eur J Obs Gynec Repr Biol. 2007;131(2):189–97.CrossRefGoogle Scholar
  49. 49.
    Karbalay-Doust S, Noorafshan A. Stereological estimation of ovarian oocyte volume, surface area and number: application on mice treated with nandrolone decanoate. Folia Histochem et Cytobiol. 2012;50(2):275–9.Google Scholar
  50. 50.
    Bassindale T, Cowan DA, Dale S, Hutt AJ, Leeds AR, Wheeler MJ, Kicmna AT. Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception. J Clin Endoc Met. 2004;89:6030–8.CrossRefGoogle Scholar
  51. 51.
    Triemstra JL, Wood RI. Testosterone self-administration in female hamsters. Behav Brain Res. 2004;154(1):221–9.Google Scholar
  52. 52.
    Bento-Silva MT, Martins MDCDC, Torres-Leal FL, Barros TL, Carvalho ILDNF, Carvalho Filho HA, Almeida FRDC. Effects of administering testosterone undecanoate in rats subjected to physical exercise: effects on the estrous cycle, motor behavior and morphology of the liver and kidney. Braz J Pharm Sci. 1985;46(1):79–89.Google Scholar
  53. 53.
    Kicman AT. Pharmacology of anabolic steroids. BJ Pharm. 2008;154(3):502–21.Google Scholar
  54. 54.
    Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: are they exaggerated? J Sports Sci Med. 2006;5(2):182–93.Google Scholar
  55. 55.
    Clark AS, Blasberg ME, Brandling-Bennett EM. Stanozolol, oxymetholone, and testosterone cypionate effects on the rat estrous cycle. Physiol Behav. 1998;63(2):287–95.Google Scholar
  56. 56.
    Malarkey WB, Strauss RH, Leizman DJ, Liggett M, Demers LM. Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. Am J Obs Gynec. 1991;165(5):1385–90.Google Scholar
  57. 57.
    Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German democratic republic government. Clin Chem. 1997;43(7):1262–79.Google Scholar
  58. 58.
    Ungerleider S. Faust’s gold: inside the East German doping machine. New York: Macmillan; 2001.Google Scholar
  59. 59.
    Spitzer G. Ranking number 3 in the world: how the addiction to doping changed sport in the GDR. In: Spitzer G, editor. Doping and doping control in Europe. Aachen: Meyer & Meyer Sport; 2006. p. 57–77.Google Scholar
  60. 60.
    Prendergast HM, Bannen T, Erickson TB, Honore KR. The toxic torch of the modern olympic games. Veter Hum Toxic. 2003;45(2):97–102.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Juan Manuel García-Manso
    • 1
    Email author
  • Teresa Valverde Esteve
    • 2
  1. 1.Department of Physical EducationUniversidad de Las Palmas de GranCanariaIslas CanariasSpain
  2. 2.Laboratorio de Investigación de Ciencias del DeporteUniversidad Católica de Valencia San Vicente MártirValenciaSpain

Personalised recommendations